Limitations in the Use of Combined Gonadotropin Releasing Hormone Analog and Human Menopausal Gonadotropin for In Vitro Fertilization
Combined gonadotropin-releasing hormone analog and human menopausal gonadotropin use in IVF is limited by high cancellation rates (20-40%) mainly due to premature luteinizing hormone surges.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
The paper discusses ovarian stimulation in IVF, focusing on the combined use of a gonadotropin-releasing hormone (GnRH) analog and human menopausal gonadotropin, with attention to premature LH surges as a major cause of cycle cancellation. It states that while stimulation protocols are tailored to patients’ hormonal status, 20–40% of patients are cancelled before ovum pick-up due mainly to premature LH surge, implying important limitations in achieving consistent ovarian control with this approach. A key caveat is that no single agent or dosage is optimal for all patients, so results depend on individual hormonal milieu and protocol adjustment rather than a universally effective regimen. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
6,327 characters
· extracted from
oa-doi-fallback
· 3 sections
· click to expand
Abstract
References
Keywords
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (20)
- Escape from the down-regulation of the pituitary-ovarian axis following decreased infusion of luteinizing hormone-releasing hormone agonist via openalex
- W1975811941 via openalex
- W1994907620 via openalex
- W2006562639 via openalex
- W2014026833 via openalex
- W2016709280 via openalex
- W2067808043 via openalex
- W2074185602 via openalex
- W2108184721 via openalex
- W2108394955 via openalex
- W2273167055 via openalex
- W2283096302 via openalex
- W2403922782 via openalex
- W2408018161 via openalex
- W2410151042 via openalex
- W2414371368 via openalex
- W2415043799 via openalex
- W2418283078 via openalex
- W1826678291 via openalex
- W2444108627 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00